Clofibrate

637-07-0

C12H15ClO3

DMSO : >= 100 mg/mL (412.03 mM); H2O : < 0.1 mg/mL (insoluble)

Cell Cycle/DNA Damage

Clofibrate is an agonist of PPAR, with EC₅₀s of 50 uM, ?500 uM for murine PPARalpha and PPARgamma, and 55 uM, ?500 uM for human PPARalpha and PPARgamma, respectively. IC50 & Target: EC50: 50 uM (Murine PPARalpha), ?500 uM (Murine PPARgamma), 55 uM (Human PPARalpha), ?500 uM (Human PPARgamma)^[1] In Vitro: Clofibrate is a PPAR agonist, with E₅₀s of 50 uM, ?500 uM for murine PPARalpha and PPARgamma, and 55 uM, ?500 uM for human PPARalpha and PPARgamma, respectively^[1]. Clofibrate (0.5, 1, 2 mM) increases FABP1 expression in two fatty acid (FA)-treated rat hepatoma cells. Clofibrate lowers ROS levels after early treatment, much more than late treatment in FA-treated cells^[2]. In Vivo: Clofibrate (0.5%) up-regulates serum concentrations and hepatic expression of FGF21 in fetuses, with a return to basal levels after Clofibrate administration withdrawal. Clofibrate administration-offspring have significantly higher expression of thermogenic genes (Ucp1, Cidea, Ppara Ppargc1a, Cpt1b) and UCP1 protein levels in response to HFD in inguinal fat, but not in retroperitoneal (combined with perirenal) or epididymal fat^[3].